Paul M. Kinsella
Partner
Paul advises on business combinations, securities offerings, and governance matters.
Experience
Matters include representation of:
- TESARO in its sale to GSK ($5.1 billion)
- NxStage in its sale to Fresenius ($2.0 billion)
- The lead underwriters in the Elanco Animal Health IPO ($1.7 billion) and the dealer managers in the exchange of Elanco stock for Lilly stock ($8.6 billion)
- Ironwood in IPO; securities and governance matters; and spin-off of Cyclerion
- Pfizer in its acquisitions of Medivation ($14 billion) and Hospira ($17 billion) and securities law matters
- Shire in acquisitions of Baxalta ($32 billion) and Dyax ($5.9 billion)
- Wright Medical in merger with Tornier ($3.3 billion) and securities and governance matters
- Cubist in sale to Merck ($9.5 billion); acquisitions of Trius, Optimer, and Adolor; and securities and governance matters
- Genzyme in sale to Sanofi ($20.1 billion); acquisitions of Bioenvision, AnorMED, Bone Care, ILEX ($1.1 billion), SangSat, Focal, GelTex ($1.3 billion) and Biomatrix; and securities and governance matters
Publications
- Co-author, “Proposed Amendments to Regulate Proxy Voting Advice and to Modernize the Shareholder Proposal Rule,” Harvard Law School Forum on Corporate Governance and Financial Regulation (November 27, 2019)
- Co-author, “A Fresh Look at Exclusive Forum Provisions,” Harvard Law School Forum on Corporate Governance and Financial Regulation (May 28, 2019)
Education
- JD, with distinction, Stanford Law School, 1993
- BA, summa cum laude, Boston College, 1988